NeuroSense Signs Term Sheet for Phase 3 PrimeC Trial in Amyotrophic Lateral Sclerosis

MT Newswires Live12-23 22:44

NeuroSense Therapeutics (NRSN) said Monday it has signed a binding term sheet with an unnamed pharmaceutical company to further develop PrimeC as potential treatment for amyotrophic lateral sclerosis in some key markets.

NeuroSense said it would keep full rights to PrimeC in other key territories.

The term sheet includes a "substantial" upfront payment" and funding for a phase 3 study as well as milestone payments and royalties on annual net sales, NeuroSense said.

A definitive agreement is expected to be finalized in Q1 2025, the company added.

NeuroSense's shares were down more than 16% in early trading Monday.

Price: 1.13, Change: -0.23, Percent Change: -16.91

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2493766371?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-12-23 22:44","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2493766371","market":"sg","top_or_hot":-1,"title":"NeuroSense Signs Term Sheet for Phase 3 PrimeC Trial in Amyotrophic Lateral Sclerosis","media":"MT Newswires Live","content":"<html><body><p> NeuroSense <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> (NRSN) said Monday it has signed a binding term sheet with an unnamed pharmaceutical company to further develop PrimeC as potential treatment for amyotrophic lateral sclerosis in some key markets.</p><p>NeuroSense said it would keep full rights to PrimeC in other key territories.</p><p>The term sheet includes a \"substantial\" upfront payment\" and funding for a phase 3 study as well as milestone payments and royalties on annual net sales, NeuroSense said.</p><p>A definitive agreement is expected to be finalized in Q1 2025, the company added.</p><p>NeuroSense's shares were down more than 16% in early trading Monday.</p><p>Price: 1.13, Change: -0.23, Percent Change: -16.91</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>NeuroSense Signs Term Sheet for Phase 3 PrimeC Trial in Amyotrophic Lateral Sclerosis</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNeuroSense Signs Term Sheet for Phase 3 PrimeC Trial in Amyotrophic Lateral Sclerosis\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-12-23 22:44 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.mtnewswires.com/><strong>MT Newswires Live</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>NeuroSense Therapeutics (NRSN) said Monday it has signed a binding term sheet with an unnamed pharmaceutical company to further develop PrimeC as potential treatment for amyotrophic lateral sclerosis ...</p>\n\n<a href=\"https://www.mtnewswires.com/\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2493766371","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2493766371","pubTimestamp":1734965048,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"NeuroSense Therapeutics  said Monday it has signed a binding term sheet with an unnamed pharmaceutical company to further develop PrimeC as potential treatment for amyotrophic lateral sclerosis in some key markets.NeuroSense said it would keep full rights to PrimeC in other key territories.The term sheet includes a \"substantial\" upfront payment\" and funding for a phase 3 study as well as milestone payments and royalties on annual net sales, NeuroSense said.A definitive agreement is expected to be finalized in Q1 2025, the company added.NeuroSense's shares were down more than 16% in early trading Monday.Price: 1.13, Change: -0.23, Percent Change: -16.91","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","NRSN":"Neurosense Therapeutics Ltd"},"translate_title":"NeuroSense签署肌萎缩侧索硬化症3期PrimeC试验条款清单","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NRSN":0.9},"content_text":"NeuroSense Therapeutics (NRSN) said Monday it has signed a binding term sheet with an unnamed pharmaceutical company to further develop PrimeC as potential treatment for amyotrophic lateral sclerosis in some key markets.NeuroSense said it would keep full rights to PrimeC in other key territories.The term sheet includes a \"substantial\" upfront payment\" and funding for a phase 3 study as well as milestone payments and royalties on annual net sales, NeuroSense said.A definitive agreement is expected to be finalized in Q1 2025, the company added.NeuroSense's shares were down more than 16% in early trading Monday.Price: 1.13, Change: -0.23, Percent Change: -16.91","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2493766371"}